JP2019516713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516713A5 JP2019516713A5 JP2018560569A JP2018560569A JP2019516713A5 JP 2019516713 A5 JP2019516713 A5 JP 2019516713A5 JP 2018560569 A JP2018560569 A JP 2018560569A JP 2018560569 A JP2018560569 A JP 2018560569A JP 2019516713 A5 JP2019516713 A5 JP 2019516713A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- prodrug
- acceptable salt
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 16
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 150000002016 disaccharides Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims 1
- -1 N, N-dimethylamino Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 *c(cc1)cc(C(Nc2nc(c(F)cc(C(F)(F)F)c3)c3[s]2)=O)c1O Chemical compound *c(cc1)cc(C(Nc2nc(c(F)cc(C(F)(F)F)c3)c3[s]2)=O)c1O 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FPMBTCSNBCPPJR-UHFFFAOYSA-N Oc(c(C(Nc([s]c1cc(F)c2)nc1c2F)=O)c1)ccc1Cl Chemical compound Oc(c(C(Nc([s]c1cc(F)c2)nc1c2F)=O)c1)ccc1Cl FPMBTCSNBCPPJR-UHFFFAOYSA-N 0.000 description 1
- MAFSZDCFTSYASZ-UHFFFAOYSA-N Oc(c(C(Nc1nc2cc(C(F)(F)F)ccc2[s]1)=O)c1)ccc1Cl Chemical compound Oc(c(C(Nc1nc2cc(C(F)(F)F)ccc2[s]1)=O)c1)ccc1Cl MAFSZDCFTSYASZ-UHFFFAOYSA-N 0.000 description 1
- GBWPHPCXGHWKOJ-UHFFFAOYSA-N Oc(ccc(Cl)c1)c1C(Nc1nc(c(C(F)(F)F)cc(F)c2)c2[s]1)=O Chemical compound Oc(ccc(Cl)c1)c1C(Nc1nc(c(C(F)(F)F)cc(F)c2)c2[s]1)=O GBWPHPCXGHWKOJ-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338190P | 2016-05-18 | 2016-05-18 | |
| US62/338,190 | 2016-05-18 | ||
| PCT/US2017/033372 WO2017201313A1 (en) | 2016-05-18 | 2017-05-18 | Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516713A JP2019516713A (ja) | 2019-06-20 |
| JP2019516713A5 true JP2019516713A5 (enExample) | 2020-06-25 |
| JP7017523B2 JP7017523B2 (ja) | 2022-02-08 |
Family
ID=60326610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560569A Active JP7017523B2 (ja) | 2016-05-18 | 2017-05-18 | 代謝性疾患および癌の治療のための新規のミトコンドリア脱共役剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10227315B2 (enExample) |
| EP (1) | EP3458454B1 (enExample) |
| JP (1) | JP7017523B2 (enExample) |
| CN (1) | CN109415363B (enExample) |
| CA (1) | CA3024610A1 (enExample) |
| WO (1) | WO2017201313A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107205971A (zh) | 2014-11-18 | 2017-09-26 | 罗格斯，新泽西州立大学 | 用于治疗代谢疾病和癌症的新的线粒体解偶联剂 |
| AU2018378935B2 (en) * | 2017-12-07 | 2024-10-31 | The Regents Of The University Of Michigan | NSD family inhibitors and methods of treatment therewith |
| FI3796975T3 (fi) * | 2018-05-22 | 2023-11-20 | Orsobio Inc | Sulfonyyliaminobentsamidijohdannaisia |
| TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| US11987579B2 (en) | 2018-07-30 | 2024-05-21 | Duke University | Niclosamide analogues and therapeutic use thereof |
| CN109503510B (zh) * | 2019-01-03 | 2020-07-03 | 山东大学 | 一种防龋抗菌的噻唑类化合物及其制备方法 |
| CA3129167A1 (en) * | 2019-02-22 | 2020-08-27 | The Regents Of The University Of California | Nonhormonal unisex contraceptives |
| WO2020231800A1 (en) * | 2019-05-10 | 2020-11-19 | Encube Ethicals Private Limited | Topical antifungal formulation |
| WO2021004477A1 (zh) * | 2019-07-09 | 2021-01-14 | 唐凌峰 | 一种基于线粒体的药物递送系统及其用途 |
| EP4583870A2 (en) * | 2022-09-08 | 2025-07-16 | Mito Biopharma, LLC | Mitochondrial uncouplers for treatment of metabolic diseases and cancer |
| CN117105809B (zh) * | 2023-10-20 | 2024-05-03 | 中国农业大学 | 一种苯甲酰苯胺化合物及其制备方法和应用 |
| CN118206492A (zh) * | 2024-03-26 | 2024-06-18 | 江南大学 | 一类2，4-二硝基苯氧基类化合物及其制备方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3147300A (en) | 1955-09-26 | 1964-09-01 | Bayer Ag | Gastropod combating salicylanilides |
| NL255279A (enExample) | 1959-08-27 | |||
| US3909816A (en) | 1974-04-29 | 1975-09-30 | Lloyd L Teeters | Flame and carbon monoxide sensor and alarm circuit |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4659738A (en) | 1985-02-15 | 1987-04-21 | The United States Of America As Represented By The Secretary Of The Army | Topical prophylaxis against schistosomal infections |
| US4983396A (en) | 1985-12-06 | 1991-01-08 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol |
| US4886783A (en) | 1986-01-31 | 1989-12-12 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agents |
| US4801586A (en) | 1986-04-23 | 1989-01-31 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agents |
| US5118845A (en) | 1986-09-29 | 1992-06-02 | Whitby Research, Inc. | Penetration enhancer for transdermal delivery of systemic agents |
| US5196410A (en) | 1986-10-31 | 1993-03-23 | Pfizer Inc. | Transdermal flux enhancing compositions |
| US4861764A (en) | 1986-11-17 | 1989-08-29 | Macro Chem. Corp. | Percutaneous absorption enhancers, compositions containing same and method of use |
| US7635722B1 (en) | 1998-07-27 | 2009-12-22 | Saint Jude Pharmaceuticals, Inc. | Chemical induced intracellular hyperthermia |
| WO2000039118A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Aromatic amides |
| EP1510207A4 (en) | 2002-06-05 | 2008-12-31 | Inst Med Molecular Design Inc | THERAPEUTIC MEDICAMENT AGAINST DIABETES |
| WO2003103656A1 (ja) | 2002-06-06 | 2003-12-18 | 株式会社医薬分子設計研究所 | Ｏ−置換ヒドロキシアリール誘導体 |
| JPWO2003103654A1 (ja) | 2002-06-10 | 2005-10-06 | 株式会社医薬分子設計研究所 | ＮＦ−κＢ活性化阻害剤 |
| AU2003249244A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| EP1575575B1 (en) | 2002-11-08 | 2010-05-19 | High Point Pharmaceuticals, LLC | Safe chemical uncouplers for the treatment of obesity |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US20050130974A1 (en) | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| US20090062396A1 (en) | 2005-05-23 | 2009-03-05 | Novo Nordisk A/S | Novel Haloalkoxy-Substituted Salicylic Anilides |
| US7749976B2 (en) | 2005-05-24 | 2010-07-06 | The Regents Of The University Of California | Isolated PTPMT1 protein which mediates insulin production and uses thereof |
| US20090291857A1 (en) | 2006-02-27 | 2009-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to identify inhibitors of the unfolded protein response |
| AU2007259143A1 (en) | 2006-06-08 | 2007-12-21 | Amgen Inc. | Benzamide derivatives and uses related thereto |
| US20110183889A1 (en) | 2007-08-29 | 2011-07-28 | The Regents Of The University Of California | Salicylanilide modified peptides for use as oral therapeutics |
| WO2009047584A1 (en) | 2007-10-11 | 2009-04-16 | Hatchtech Pty. Ltd. | Combination compositions and methods of use of the same for controlling infestation |
| US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| US20100190832A1 (en) | 2008-10-17 | 2010-07-29 | National Institute Of Immunology. | Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates |
| EP2609089A1 (en) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| WO2012040223A2 (en) | 2010-09-21 | 2012-03-29 | North Carolina Central University | Method for treating non-alcoholic fatty liver disease and type-ii diabetes |
| CA2846227A1 (en) | 2010-11-16 | 2012-05-24 | University Of Medicine And Dentistry Of New Jersey | Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers |
| KR101434461B1 (ko) | 2011-10-21 | 2014-09-01 | 한국생명공학연구원 | 2-하이드록시아릴아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| KR102200176B1 (ko) | 2012-05-08 | 2021-01-11 | 에어로믹스, 인코포레이티드 | 신규 방법 |
| US20130324555A1 (en) | 2012-05-29 | 2013-12-05 | Richard Delarey Wood | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals |
| ES2784223T3 (es) | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina |
| US10005720B2 (en) * | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| US10351527B2 (en) * | 2014-04-09 | 2019-07-16 | The University Of British Columbia | Binding function 3 (BF3) site compounds as therapeutics and methods for their use |
| US20170216252A1 (en) * | 2014-07-11 | 2017-08-03 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| CN104230787B (zh) | 2014-08-20 | 2016-08-24 | 华东师范大学 | N-(1，3-二氧代异吲哚啉)芳酰胺类化合物及其制备方法和应用 |
| CN107205971A (zh) * | 2014-11-18 | 2017-09-26 | 罗格斯，新泽西州立大学 | 用于治疗代谢疾病和癌症的新的线粒体解偶联剂 |
-
2017
- 2017-05-18 CA CA3024610A patent/CA3024610A1/en active Pending
- 2017-05-18 JP JP2018560569A patent/JP7017523B2/ja active Active
- 2017-05-18 US US15/599,177 patent/US10227315B2/en active Active
- 2017-05-18 WO PCT/US2017/033372 patent/WO2017201313A1/en not_active Ceased
- 2017-05-18 CN CN201780042524.9A patent/CN109415363B/zh active Active
- 2017-05-18 EP EP17800184.8A patent/EP3458454B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516713A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2019518071A5 (enExample) | ||
| JP2019515952A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2015024998A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2016529324A5 (enExample) | ||
| JP2017511321A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2017515901A5 (enExample) | ||
| RU2003137561A (ru) | 4-замещенные нуклеозиды | |
| JP2013503846A5 (enExample) | ||
| JP2017505785A5 (enExample) | ||
| CA2750413A1 (en) | Hydroxamic acid derivatives | |
| GT200500221A (es) | Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan. | |
| JP2008540554A5 (enExample) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2020507589A5 (enExample) | ||
| JP2012532883A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2015535847A5 (enExample) | ||
| RU2006135541A (ru) | Производные аминокислот | |
| RU2016133471A (ru) | Композиции и способы для лечения диабета и заболеваний печени | |
| JP2015536997A5 (enExample) |